{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-262543","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2024-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.400993+00:00","generated_at":"2026-05-29T21:43:30.173451+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Forte Biosciences raises $53M in oversubscribed private placement for FB102 clinical development","bullets":["Gross proceeds ~$53M from shares and pre-funded warrants to institutional investors including OrbiMed, Janus Henderson, Tybourne.","Private placement expected to close November 21, 2024; net proceeds for working capital and general corporate purposes.","FB102 healthy volunteer study completed; celiac disease trial topline readout projected Q2 2025.","Additional indications expected over next 12 months; R&D Day on December 3, 2024.","CEO Paul Wagner says financing is transformative and well capitalized for continued advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-262543","json":"https://secwatch.observer/filing/0001193125-24-262543.json","markdown":"https://secwatch.observer/filing/0001193125-24-262543.md","text":"https://secwatch.observer/filing/0001193125-24-262543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524262543/0001193125-24-262543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524262543/d815860d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T21:43:30.173451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}